126 results about "Antiparasitic Drugs" patented technology

This invention relates to pesticide and antiparasitic compositions for the control of pests, diseases and parasites attacking plants and animals. The compositions include, at least one chitinolytic agent or a chitinolytic activity-inducing agent, and sulfide or a sulfide-producing agent from microorganisms or chemical compounds, wherein the chitinolytic agent or the chitinolytic activity-inducing agent and sulfur or a sulfur-producing agent obtaining from microorganisms or chemical compounds are concurrently applied at a range significantly lower than any of the above-mentioned compounds, when they are individually to attain effective control.

The invention relates to the treatment of viral, bacterial, parasitic, proliferative diseases, neurodegenerative diseases, inflammatory diseases, immunological diseases, transplanted organ rejection, and diseases produced by intoxication with heavy metals. The invention relates to the use of specific metal chelating agents including, furoic acid, 2-thiophenecarboxylic acid and their derivatives, analogs and structurally related chemicals as pharmacological agents that can be used effectively to disrupt and inactivate specific transition metal ion containing zinc finger structural motifs in metalloproteins and specific transition metal ion containing catalytic sites in metalloproteinases, which in turn, inactivate the pathogenic virus, pathogenic prokaryotic or eukaryotic cells which produces disease conditions. The preparations can be administered topically or for systemic use. The preparations are novel wide-spectrum antibiotics which have antiviral, antiproliferative, antineoplastic, antiangiogenic, antibacterial, antiparasitic, antiinfective, and anti-inflammatory effects and can be used in the treatment and prevention of diseases such as AIDS, cancers, untoward angiogenesis, pulmonary anthrax, malaria, inflammatory responses, Alzheimer's disease and other diseases.

The present invention includes methods and compositions for the treatment and prevention of protozoal parasitic infections utilizing Diindolylmethane-related indoles. Additive and synergistic interaction of Diindolylmethane-related indoles with other known anti-parasitic and pro-apoptotic agents is believed to permit more effective therapy and prevention of protozoal parasitic infections. The methods and compositions described provide new treatment of protozoal parasitic diseases of mammals and birds including malaria, leishmaniasis, trypanosomiasis, trichomoniasis, neosporosis and coccidiosis.

The invention relates to a series of tenvermectin derivatives obtained by modification of tenvermectin A and/or tenvermectin B show in a following formula and a purpose of the tenvermectin derivatives on an anti-parasitic aspect. The control objects of the tenvermectin derivatives relate to parasites on agriculture and forestry crops, people, birds and beasts, and aquatic products. The derivatives have the advantages of good effect, low toxicity, and environment friendliness.

The present invention provides a novel class of compounds that disrupt the parasitic infectious life cycle and serve as promising agents for anti-parasitic therapy.

The invention relates to an anti-parasitic ivermectin transdermal solution used for livestock and a preparation method thereof. The anti-parasitic ivermectin transdermal solution comprises the following components respectively according to parts by volume: 5 to 15 parts of ethyl acetate, 20 to 30 parts of dimethyl sulfoxide, 2 to 6 parts of azone, 1 to 3 parts of isopropanol and 50 to 70 parts of propanediol; and the content of ivermectin is 0.3g to 1g in a solution of 100ml, and the finished product is prepared by the processes of dissolving, mixing, filtering and filling. The azone related in the prescription of the invention is a novel skin penetration enhancer, can increase the transdermal absorption of the skin to various medicines of different types, effectively avoids the pass effect of hepar, avoids peak and valley phenomena in the absorption process of the medicine, reduces the toxic or side effect caused by the correlative dosage in the medicine, prolongs the effective effect time, changes the administration area, effectively regulates the administration dosage and reduces differences among individuals. The invention has the characteristic of simple, convenient and fast use, and is more suitable for the anti-parasitic prevention and treatment of a pasturing area compared with other preparation forms.

The invention discloses the eugenic nanometer drug, comprising isopropyl microstate, croton oil, vitamin E oil, tuwen-80, spans-80 and eugenic. The drug has the advantages of improving the antibiosis, anti-inflammation, disinfection, analgesic, and ant parasitic. So the drug is green, safe and highly effective ant parasitic agent.

The invention provides a broad-spectrum antiparasitic drug nanoemulsion and a preparation method thereof, which comprises the following components by weight percentage: 5-20% of fenbendazole, 0.3%-3% of ivermectin, and 0.5% of oil phase %-7%, co-surfactant 2%-12%, co-solvent 2%-5%, surfactant 10%-30%, deionized water 3-40%. The antiseptic property obtained by the invention is better, and it will not be mildewed or discolored after being placed at room temperature for three months. No additional preservatives are required, and the shelf life is long.

The invention discloses an Artesunate nanoemulsion drug that is an O/W (oil-in-water type) nanoemulsion system consisting of ethyl oleate, Tween-80, normal butanol, ultrapure water and Artesunate. The nanoemulsion drug effectively overcomes the first-pass effect of traditional tablets in liver, causes no sense of pain in injection and greatly improves the insecticidal and helminthic effect of original Artesunate. Meanwhile, the nanoemulsion system has high drug-loading rate, is stable when stored, has certain slow release function compared with merchant Artesunate injection, and further is convenient for administration, thus greatly improving the bioavailability. Besides, shown by acute toxicity tests and clinical drug effect tests on mice, the nanoemulsion has no obvious toxic or side effect and is a safe, reliable and high-efficiency nano level antiparasitic drug.

The invention belongs to the technical fields of antiparasitic drugs for animals, and preparation methods thereof, and concretely relates to a suspension containing albendazole, and a preparation method thereof. The above preparation comprises an albendazole bulk drug, a suspending aid, a wetting agent, an antiseptic and a flocculating agent. The suspension containing albendazole is prepared through a dispersion process, and is an off-white sticky water suspension. The suspension containing albendazole developed in the invention has the advantages of good stability, good palatability, long elimination half life, and high bioavailability, and can be used by animals as an oral preparation.

The functions of IFNgamma-induced GTPases of the IGTP-family as strong anti-infective agents, and more particularly a strong anti-parasite and/or anti-bacterial agents, are disclosed. These molecules (in both protein and nucleic acid forms) are effective to modify anti-microbial e.g., anti-bacterial and/or anti-parasitic) immune responses in a subject, to prevent or inhibit replication or infectivity of microbe, to treat microbial diseases, and to detect susceptibility of a subject to microbial infection. This invention also provides kits and compounds useful in such methods. Also provided are transgenic non-human animals in which IGTP-family member gene expression has been altered, and the use of such animals to screen for anti-microbial agents.

The invention discloses compounds and an application thereof in preparation of anti-parasitosis drugs. The compounds have a structural formula represented by the formula I or the formula II. The compounds provided by the invention have rich functional group diversity and modificability, and the products are relatively easy to separate and purify. The compounds provided by the invention have quite good inhibitory effect on pernicious malaria NDH protein activity and are new anti-malarial action targets and mechanisms, and thus the compounds also have quite good inhibitory effect on many plasmodium species and strains generating resistance to traditional drugs, thereby providing a new breakthrough for current increasingly-serious plasmodium drug resistance aspect. At the same time, the plasmodium NDH and human NADH oxidordeuctase belong to different species, so that the compounds can be expected to produce fewer side effects on human. In summary, the compounds have broad development and application prospects.

The invention describes a long-acting composition comprising a spiro-azetidine isoxazoline of Formula (1) or (2) wherein R^1a, R^1b, R^1c and R² are as described herein, and stereoisomers thereof. The composition is a veterinary composition and also comprises a glycol ether and at least one veterinarily acceptable solvent, and optionally, at least one precipitation inhibitor, antioxidant and additional veterinary agent, and any mixture thereof. The invention also includes a method of treating an animal with a parasitic infestation by administering the long-acting composition to the animal in need thereof.

The invention discloses a group of substituted benzoheterocycle amine derivatives and a preparation method and related application thereof as an IMPDH (inosine monophosphate dehydrogenase) inhibitor. The IMPDH inhibitor has good application prospects in virus resistance, immunosuppression, tumor resistance, bacterium resistance, parasite resistance and the like. In the invention, a new-structure IMPDH inhibitor shown by the formula (I) is obtained through the design, synthesis and activity screening study on an active compound targeting IMPDH, and a foundation is laid for the development and application of the compounds as the medicines and medicinal compositions thereof with related effects such as virus resistance, tumor resistance, immunosuppression and the like.

The invention provides a carbazole alkamine compound and a preparation method thereof and application for a parasitic disease resistance aspect. Specifically, the invention provides a racemic modification of the compound shown as type (A) and an enantiomer or salt capable of being accepted by pharmacy of the enantiomer. The compound has excellent anti-schistosoma and anti-hydatid cyst activity. According to the carbazole alkamine compound and the preparation method thereof and the application for the parasitic disease resistance aspect, the design is reasonable, the source of used raw materials is wide, the preparation method is easy and convenient and suitable for utility and can be applied to parasitic disease resistance drug preparation. Type A (please see the specifications for the chemical structural formula)

The present invention relates to veterinary or pharmaceutical antiparasitic formulations which may comprise a macrocyclic lactone, one or more alcohol cosolvents and an oil wherein the crystallization of the macrocyclic lactone is minimalized. This invention also provides for, inter alia, antiparasitic formulations for the treating, controlling and preventing of endo- and ectoparasite infections in warm-blooded animals, such as livestock.

The invention discloses a compound and application of the compound in preparation of drugs for resisting parasitic diseases. The compound has the chemical formula (VII), in the chemical formula (VII), L is O or CH2, one of R1 and R2 is a halogen element, and the other is H. The compound provided by the invention belongs to a quinolones compound; through research, an inventor finds that the compound can inhibit activity of NDH-2 protein of plasmodium, and therefore, the compound can be used for slowing down the clinical symptoms at asexual reproduction stage and also can be used for stopping diseases spreading at the sexual reproduction stage of life cycle of plasmodium. The compound has great significances for treating the plasmodium diseases. The chemical formula (VII) is as shown in the specification.

The invention provides a Chinese herbal medicine feed for grass carps. The Chinese herbal medicine feed comprises the following Chinese herbal medicine components in percentage by weight: 20-30% of fish meal, 20-30% of corn, 13-18% of astragalus membranaceus, 8-12% of radix isatidis, 10-15% of licorice, 5-8% of folium isatidis, 6-8% of codonopsis pilosula, 3-5% of rheum officinale, 5-8% of rhizoma phragmitis, 10-15% of tribulusterrestris, 8-12% of white poria and 5-10% of pericarpium granati. According to the Chinese herbal medicine feed provided by the invention, the Chinese herbal medicine contains a variety of immune competent matters, and thus the capacity of promoting the ingestion of the grass carps to increase the food ration of the grass carps is realized, an antiparasitic drug component is contained, and thus the immunity of the grass carps is improved, the somaticsubstances of the grass carps is enhanced, the quality of sperm eggs of the grass carps is enhanced to increase the sperm egg combination rate of the grass carps in a multiplicative process, further the hatchability of fish fries is high and the quality of the fish fries is good; the Chinese herbal medicine feed is simple in production process, and low in cost and raw materials are convenient to obtain.

An anti-parasiticidal composition presented as a topical “pour-on” product for treating animals infected by parasites which are known to be susceptible to salicylanilides, especially closantel, alone or together with at least one other anti parasitic compound of the avermectin or milbemycin type and offers enhanced bioavailability of the salicylanilide by provision of a delivery system comprising at least 20% (v/v) of one or more alcohols, and optionally including a polymeric moiety selected from the group consisting of polyvinylpyrrolidone (PVP), polyoxypropylene/polyoxyethylene block copolymers (poloxamer), and polyethylene glycols (PEG), thereby improving the bioavailability of e.g. closantel (as assessed with respect to blood plasma levels of closantel).

The use of levo-ornidazole in the preparation of anti-parasitic infection drug is provided. It is demonstrated that levo-ornidazole is superior to dextro-ornidazole and racemic ornidazole in the therapeutic action against parasitization (especially trichomonas vaginalis infection and cecal amoeba infection), and thus it is more practicable to formulate L-ornidazole as anti-parasitic infection drugs, and particularly as drug preparations which are suitable for clinical uses, including oral preparation, intravenous preparation and vaginal preparation.